On October 4, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that total 3 innovative clinical Phase II data of Timdarpacept (IMM01), the first SIRPαFc fusion protein targeting human CD47 in China, will be reported at the 2023 American Society of Hematology (ASH) Annual Meeting. Two phase II clinical data summary, for first-line MDS therapy and for cHL indications after PD1 antibody treatment failure will be presented orally, research results of first-line for CMML indication were presented in form of poster.